• Publications
  • Influence
Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV.
In 2008, 25 years after the human immunodeficiency virus (HIV) was discovered as the then tentative aetiological agent of acquired immune deficiency syndrome (AIDS), exactly 25 anti-HIV compoundsExpand
  • 516
  • 25
  • PDF
The AMD3100 story : The path to the discovery of a stem cell mobilizer (Mozobil)
AMD3100 was found to inhibit HIV-1 and HIV-2 within the 1-10nM concentration range while not being toxic to the host cells at concentrations up to 500 microM, thus achieving a selectivity index ofExpand
  • 173
  • 8
Another ten stories in antiviral drug discovery (part C): "Old" and "new" antivirals, strategies, and perspectives.
The ten stories told here deal with (i) ribavirin as an inhibitor of IMP dehydrogenase and (ii) ribavirin, in combination with pegylated interferon, as the present “standard of care” for hepatitis C;Expand
  • 65
  • 6
Antivirals and antiviral strategies
  • E. Clercq
  • Biology
  • Nature Reviews Microbiology
  • 1 September 2004
In recent years, the demand for new antiviral strategies has increased markedly. There are many contributing factors to this increased demand, including the ever-increasing prevalence of chronicExpand
  • 175
  • 4
  • PDF
The history of antiretrovirals: key discoveries over the past 25 years.
Within 25 years after zidovudine (3′-azido-2′,3′-dideoxythymidine, AZT) was first described as an inhibitor of HIV replication, 25 anti-HIV drugs have been formally approved for clinical use in theExpand
  • 145
  • 4
Current race in the development of DAAs (direct-acting antivirals) against HCV.
The direct-acting antivirals (DAAs) currently in development for treatment of hepatitis C fall into four categories: (i) NS3/4A protease inhibitors: ABT-450/r, faldaprevir, asunaprevir, GS-9256,Expand
  • 65
  • 3
The nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors in the treatment of HIV infections (AIDS).
Abstract The majority of the drugs currently used for the treatment of HIV infections (AIDS) belong to either of the following three classes: nucleoside reverse transcriptase inhibitors (NRTIs),Expand
  • 49
  • 3
Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF)
Tenofovir alafenamide (TAF) can be considered a new prodrug of tenofovir (TFV), as successor of tenofovir disoproxil fumarate (TDF). It is in vivo as potent against human immunodeficiency virus (HIV)Expand
  • 71
  • 2
  • PDF
John Montgomery's legacy: carbocyclic adenosine analogues as SAH hydrolase inhibitors with broad-spectrum antiviral activity.
Ever since the S-adenosylhomocysteine (AdoHcy, SAH) hydrolase was recognized as a pharmacological target for antiviral agents (J. A. Montgomery et al., J. Med. Chem. 25:626–629, 1982), an increasingExpand
  • 46
  • 2
Abstract Starting from protected hexenetriol, acyclic analogues of the 1,5-anhydrohexitol nucleosides were synthesized. The reaction sequence involved a stereoselective Sharpless dihydroxylation andExpand
  • 24
  • 2